Rituximab, a lower-cost treatment, may be as effective at managing RRMS as the approved therapy Ocrevus, a new study from ...

The Global Multiple Sclerosis Drugs Market achieved a valuation of $23.2 Billion in 2024 and is anticipated to exceed $53.25 ...

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with ...

Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called ...

A new artificial intelligence (AI) tool that can help interpret and assess how well treatments are working for patients with multiple sclerosis (MS) has been developed.

Hauser's work on multiple sclerosis (MS) started more than 45 years ago ... Then 27 years old, he decided to make it his life ...

When the immune system does not function properly, individuals become more susceptible to infections caused by viruses, bacteria, or fungi.

There is no known cure for multiple sclerosis. Treatments attempt to return function after an attack, prevent new attacks, and prevent disability. MS medications can have adverse effects or be ...

Ageing is associated with significant immunological changes that can influence both the progression of the disease and the ...

UK researchers have developed a new artificial intelligence (AI) tool that can help interpret and assess how well treatment ...

Alberto Ascherio and Stephen Hauser were recognized for their work uncovering the role of B cells and Epstein Barr virus in ...

A Cleveland Clinic-led clinical trial of tolebrutinib, an investigational oral Bruton's tyrosine kinase inhibitor, a group of drugs originally developed to treat lymphomas and related blood disorders, ...